21st APRIL NICE APPROVES AVELUMAB Neuroendocrine Cancer UK is delighted to share with you NICE’s approval of Avelumab as a first line therapy option in metastatic MCC. Avelumab is now recommended as an option for treating metastatic Merkel cell carcinoma in adults...
Yesterday, Monday April 19th, NICE launched their 2021-2026 strategy ” a vision for the future”. According to NICE – Public and patients will see: – An interactive guideline structure that facilitates links to the underpinning evidence and...
NCUK is excited to announce that its review article “The Role of Patient Support Groups in Neuroendocrine Neoplasms”, co-authored by Catherine Bouvier and Teodora Kolarova (International Neuroendocrine Cancer Alliance), has been accepted for publication in Current...
